FDA Streamlines Biosimilar Testing to Cut Drug Costs
WASHINGTON — A comprehensive review by Reuters, US News, Center for Biosimilars and FiercePharma confirms significant developments in fda streamlines biosimilar testing to cut drug costs. The following key points…